Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Neuphoria Therapeutics Inc (NASDAQ: NEUP) closed at $4.36 in the last session, down -4.39% from day before closing price of $4.56. In other words, the price has decreased by -$4.39 from its previous closing price. On the day, 0.1 million shares were traded. NEUP stock price reached its highest trading level at $4.4624 during the session, while it also had its lowest trading level at $4.13.
Ratios:
We take a closer look at NEUP’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.44. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 28, 2023, Maxim Group reiterated its Buy rating and also lowered its target price recommendation from $7 to $10.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $54.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $54 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 21 ’25 when Lynx1 Capital Management LP bought 639,110 shares for $5.14 per share. The transaction valued at 3,283,108 led to the insider holds 875,328 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEUP now has a Market Capitalization of 23445156 and an Enterprise Value of 9913736. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.52 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 0.633 whereas that against EBITDA is -4.404.
Stock Price History:
The Beta on a monthly basis for NEUP is 0.50, which has changed by 0.26666665 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, NEUP has reached a high of $21.40, while it has fallen to a 52-week low of $2.77. The 50-Day Moving Average of the stock is -52.78%, while the 200-Day Moving Average is calculated to be -41.32%.
Shares Statistics:
According to the various share statistics, NEUP traded on average about 1.54M shares per day over the past 3-months and 113570 shares per day over the past 10 days. Insiders hold about 20.74% of the company’s shares, while institutions hold 71.93% stake in the company. Shares short for NEUP as of 1763078400 were 166591 with a Short Ratio of 0.11, compared to 1760486400 on 13622. Therefore, it implies a Short% of Shares Outstanding of 166591 and a Short% of Float of 3.1.
Earnings Estimates
The dynamic stock of Neuphoria Therapeutics Inc (NEUP) is currently attracting attention from 1 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.31 and low estimates of -$1.31.
Analysts are recommending an EPS of between -$5.26 and -$5.26 for the fiscal current year, implying an average EPS of -$5.26. EPS for the following year is -$3.23, with 2.0 analysts recommending between -$1.21 and -$5.26.
